Results 1 to 10 of about 3,004 (115)

Administration of eptifibatide as rescue therapy during mechanical thrombectomy in acute ischemic stroke [PDF]

open access: yesFrontiers in Neurology
BackgroundThe success of the technical implementation of mechanical thrombectomy (MT) depends on many factors. Considering the experience of the interventional radiologist and the anatomical vascular differences of individual patients, it has technical ...
David Cernik   +8 more
doaj   +2 more sources

Protective effects of combined eptifibatide and ticagrelor in patients with unstable angina undergoing percutaneous coronary intervention: a single-center experience [PDF]

open access: yesBMC Cardiovascular Disorders
Background We evaluated the safety and effectiveness of combined eptifibatide and ticagrelor in patients with unstable angina pectoris undergoing percutaneous coronary intervention (PCI).
Shangsong Shi   +4 more
doaj   +2 more sources

Evaluation of the real-world safety of eptifibatide in the treatment of ARDS: results of a disproportionality analysis of FAERS data [PDF]

open access: yesFrontiers in Medicine
BackgroundAcute respiratory distress syndrome (ARDS) is a clinical syndrome with an extremely high mortality rate, and antiplatelet therapy is an important treatment approach.
Peng Zhang   +5 more
doaj   +2 more sources

Comparative Effects of Glenzocimab and Eptifibatide on Bleeding Severity in 2 Mouse Models of Intracranial Hemorrhage [PDF]

open access: yesJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Antiplatelet drugs represent potential candidates for protecting the penumbral microcirculation during cerebral ischemia and improving the benefits of arterial recanalization in ischemic stroke.
Sébastien Dupont   +18 more
doaj   +2 more sources

Eptifibatide bolus dose postductal stenting intervention: A single-center experience [PDF]

open access: yesAnnals of Pediatric Cardiology
Objectives: Stent thrombosis, a potential complication of ductal stenting, is associated with high mortality. This is a catastrophic complication, which can occur acutely (within 24 h), subacutely (within 30 days), or late (≥30 days) after stent ...
Rishika Mehta   +5 more
doaj   +2 more sources

Acute Profound Thrombocytopenia Induced by Eptifibatide Causing Diffuse Alveolar Hemorrhage

open access: yesCase Reports in Critical Care, 2021
Background. Eptifibatide is a glycoprotein IIb/IIIa (GP IIb/IIIa) receptor inhibitor which prevents platelet activation. The mechanism in which eptifibatide causes profound thrombocytopenia is poorly understood. One hypothesis suggests antibody-dependent
Gregory Byrd   +5 more
doaj   +1 more source

Results of a pilot clinical trial of the safety and efficacy of an original glycoprotein IIb/IIIa receptor inhibitor in acute coronary syndrome

open access: yesКардиоваскулярная терапия и профилактика, 2023
Aim. To study the safety and efficacy of Angipure in acute ST-segment elevation coronary syndrome (STE-ACS) and high-risk percutaneous transluminal coronary angioplasty (PTCA) compared with eptifibatide.Material and methods.
S. V. Lukyanov   +6 more
doaj   +1 more source

Application of eptifibatide injection in acute ischemic cerebrovascular disease [PDF]

open access: yesXin yixue, 2022
Objective To evaluate the treatment effectiveness and safety of eptifibatide injection in the treatment of acute ischemic cerebrovascular disease (ICVD).
Mei Ni, Tian Liang
doaj   +1 more source

Acute Stent Thrombosis Associated with Eptifibatide-Induced Profound Thrombocytopenia

open access: yesCase Reports in Cardiology, 2020
Background. Eptifibatide is an inhibitor of the platelet glycoprotein (GP) IIb/IIIa receptor that is commonly used in patients undergoing percutaneous coronary intervention (PCI). Case.
Amer Aljundi, Alaa Rahhal, Wafer Dabdoob
doaj   +1 more source

Effects of two different glycoprotein platelet IIb/IIIa inhibitors and the clinical endpoints in patients with intracranial Pipeline flow diverter implant

open access: yesJournal of Interventional Medicine, 2020
Objective: To compare the antiplatelet effect and major adverse cerebrovascular events of Pipeline for intracranial aneurysms using glycoprotein IIb/IIIa antagonists (GPI) eptifibatide and tirofiban.
Qiao Deng   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy